恶性疾病的造血干细胞治疗
Hematopoietic stem cell therapy for malignant diseases.
作者信息
Shapira Michael Y, Hai Ali Abdul, Tsirigotis Panagiotis, Resnick Igor B, Or Reuven, Slavin Shimon
机构信息
Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah University Hospital, Jerusalem 91120, Israel.
出版信息
Ann Med. 2007;39(6):465-73. doi: 10.1080/07853890701472323. Epub 2007 Jul 5.
Allogeneic bone marrow or blood stem cell transplantation (SCT) has changed its face in the last two decades. The introduction of nonmyeloablative conditioning regimens has reduced procedure toxicity and allowed the application of SCT in patients and conditions in which SCT was not offered in the past. In this review we will summarize the changes and accomplishments achieved in the past years in the field of stem cell transplantation for malignant disorders.
在过去二十年中，异基因骨髓或造血干细胞移植（SCT）已焕然一新。非清髓性预处理方案的引入降低了手术毒性，并使SCT能够应用于过去未接受SCT治疗的患者和病情。在本综述中，我们将总结过去几年在恶性疾病干细胞移植领域所取得的变化和成就。
Zotero 插件